Rilonacept
drugOn this page
Also known as ArcalystIL-1 TRAPINTERLEUKIN-1 TRAPKpl-914
Summary
Rilonacept (CHEMBL1201830) is an approved protein (ATC L04AC04); indicated across 13 conditions including immune system disorder and cryopyrin-associated periodic syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: L04AC04
- Indications: 13 conditions
- Clinical trials: 26
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201830 |
| Name | Rilonacept |
| Type | Protein |
| Max phase | 4 |
| ATC | L04AC04 |
Also known as: Arcalyst, IL-1 TRAP, INTERLEUKIN-1 TRAP, Kpl-914, KPL-914, Rilonacept, RILONACEPT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
13 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| cryopyrin-associated periodic syndrome | 4 | MONDO:0016168 | Orphanet:47045 |
| pericarditis | 4 | MONDO:0005904 | EFO:0007427 |
| gout | 3 | MONDO:0005393 | EFO:0004274 |
| juvenile idiopathic arthritis | 2 | MONDO:0011429 | EFO:0002609 |
| alcoholic hepatitis | 2 | MONDO:0001505 | EFO:1001345 |
| familial Mediterranean fever | 2 | MONDO:0018088 | MONDO:0018088 |
| cold urticaria | 2 | MONDO:0022799 | EFO:1001881 |
| diffuse scleroderma | 1 | MONDO:0005019 | EFO:0000404 |
| type 1 diabetes mellitus | 1 | MONDO:0005147 | MONDO:0005147 |
| hearing loss disorder | 0 | MONDO:0005365 | EFO:0004238 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 26.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 13 |
| PHASE3 | 7 |
| PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01663103 | PHASE4 | COMPLETED | Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) |
| NCT00288704 | PHASE3 | COMPLETED | Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) |
| NCT00829829 | PHASE3 | COMPLETED | PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 |
| NCT00855920 | PHASE3 | COMPLETED | Study Utilizing Rilonacept in Gout Exacerbations |
| NCT00856206 | PHASE3 | COMPLETED | Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) |
| NCT00958438 | PHASE3 | COMPLETED | PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) |
| NCT01459796 | PHASE3 | TERMINATED | Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares |
| NCT03737110 | PHASE3 | COMPLETED | Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis |
| NCT06660732 | PHASE2 | RECRUITING | Rilonacept in Subjects With Cardiac Sarcoidosis |
| NCT00094900 | PHASE2 | COMPLETED | Interleukin-1 Trap to Treat Autoinflammatory Diseases |
| NCT00417417 | PHASE2 | COMPLETED | Rilonacept to Improve Artery Function in Patients With Atherosclerosis |
| NCT00534495 | PHASE2 | COMPLETED | Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults |
| NCT00582907 | PHASE2 | COMPLETED | Rilonacept for Treatment of Familial Mediterranean Fever (FMF) |
| NCT00609544 | PHASE2 | WITHDRAWN | Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia |
| NCT00610363 | PHASE2 | COMPLETED | Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares |
| NCT00897715 | PHASE2 | COMPLETED | Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra) |
| NCT01045772 | PHASE2 | COMPLETED | Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) |
| NCT01538719 | PHASE1/PHASE2 | COMPLETED | IL1-TRAP, Rilonacept, in Systemic Sclerosis |
| NCT01801449 | PHASE2 | COMPLETED | Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) |
| NCT01903798 | PHASE2 | COMPLETED | A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis |
| NCT02171416 | PHASE2 | COMPLETED | Cold Contact Urticaria Treatment With Rilonacept |
| NCT03980522 | PHASE2 | COMPLETED | A Pilot Study of KPL-914 in Recurrent Pericarditis |
| NCT00962026 | PHASE1 | COMPLETED | Rilonacept in Diabetes Mellitus Type 1: Safety Study |
| NCT01803321 | PHASE1 | COMPLETED | Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) |
| NCT02828033 | EARLY_PHASE1 | UNKNOWN | Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss |
| NCT01830699 | Not specified | COMPLETED | Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).